Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

Inpatient immune checkpoint inhibitor treatment produces poor outcomes across cancer types, according to the largest study of its kind.

A cancer 'vaccine' developed by a Yale University scientist kept people's kidney cancer from recurring for three years, ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Summit Therapeutics Inc.

Discover insights from Summit Therapeutics' Q4 2024 earnings call, highlighting the Pfizer collaboration, ivonescimab trial expansions, and strong ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith Zaslavsky, CEO of Ignite Proteomics and IMAC Holdings. “Our analysis shows ...

Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...

A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...